Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: Christian Gratzke Clear advanced filters

  • Prostate cancer growth depends on de novo lipogenesis controlled by the mitochondrial pyruvate dehydrogenase complex (PDC). Here the authors find that a histone methyltransferase KMT9 is localized in the mitochondria of prostate cancer cells to regulate PDC activity by methylating its subunit DLAT.

    • Yanhan Jia
    • Sheng Wang
    • Roland Schüle
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-14

  • Urothelial cancer is a challenging disease and an emerging field for targeted therapies. Here, the authors optimize clinical proteomics to provide proteome-level data on tumor specificity and identify robust prognostic subtypes with predictive information for repurposed drug candidates.

    • Franz F. Dressler
    • Falk Diedrichs
    • Ákos Végvári
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-19

  • Cannabinoid receptors and their agonists, endocannabinoids, can be detected throughout the urinary tract. However, despite a paucity of well-tolerated agents for patients with lower urinary tract symptoms (LUTS), clinical targeting of this system has remained largely overlooked. In this Review, the authors describe the current evidence for a role of cannabinoids in micturition and as a treatment for LUTS.

    • Petter Hedlund
    • Christian Gratzke
    Reviews
    Nature Reviews Urology
    Volume: 13, P: 463-470

  • Interest is growing in minimally invasive treatment options male lower urinary tract symptoms (LUTS), and preservation of all aspects of sexual function is increasingly important for patients. Here, the authors discuss initial experimental data on new minimally invasive procedures, such as the intraprostatic injection of novel agents, and the mechanical prostatic urethral lift device—Urolift®(Neotract, Inc., USA) for the treatment of LUTS caused by BPH.

    • Giuseppe Magistro
    • Christian G. Stief
    • Christian Gratzke
    Reviews
    Nature Reviews Urology
    Volume: 12, P: 461-471

  • Urethral and prostatic α1-adrenoreceptors are thought to mediate the dynamic component of benign prostatic obstruction. Pharmacologic antagonists of these receptors can notably improve symptoms, even in patients who have undergone prostatectomy. This Review provides an update on the distribution of α1-adrenoreceptors in relevant urinary tract structures and how this might affect therapy with antagonists.

    • Karl-Erik Andersson
    • Christian Gratzke
    Reviews
    Nature Clinical Practice Urology
    Volume: 4, P: 368-378

  • Cancer sequencing studies have revealed that urothelial carcinomas harbour recurrent mutations in multiple genes that control epigenetics. A major challenge for basic and clinical researchers is to convert this genetic information into biological and pathological insights, as well as to tailor novel therapeutic modalities for individual patients with bladder cancer.

    • Ian J. Frew
    • H. T. Marc Timmers
    • Christian Gratzke
    Comments & Opinion
    Nature Reviews Urology
    Volume: 17, P: 655-656

  • Chimeric antigen receptor T cell immunotherapy for prostate cancer has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy; furthermore, new developments could improve the efficacy of chimeric antigen receptor T cell therapy and this treatment could also be applied as focal therapy for this disease.

    • Philipp Wolf
    • Jamal Alzubi
    • Toni Cathomen
    Reviews
    Nature Reviews Urology
    Volume: 18, P: 556-571